ACR Congress Review 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Patient-reported outcomes with JAK inhibitors<br />
Upadacitinib<br />
Patient-reported outcomes with upadacitinib in RA<br />
Several posters presented data on PROs with upadacitinib in the Phase 3 SELECT studies.<br />
Fleischmann and colleagues presented a 26-week analysis of PROs with upadacitinib and adalimumab<br />
in the Phase 3 SELECT-COMPARE study. This ongoing Phase 3 study randomised patients with<br />
moderately to severely active RA and inadequate responses to MTX to receive upadacitinib 15 mg QD,<br />
adalimumab 40 mg EOW, or placebo while on background MTX therapy. Patients treated with<br />
upadacitinib or adalimumab reported clinically meaningful changes from baseline in all PtGA, pain VAS,<br />
HAQ, FACIT-F, and duration and severity of AM stiffness at Week 26. Higher proportions of patients<br />
receiving upadacitinib (74% to 84% of patients) continued to have clinically meaningful responses from<br />
Week 12 to 26 than with adalimumab (66% to 70% of patients; all P values
Change language